327 related articles for article (PubMed ID: 2851191)
1. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
2. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
Shimotori T; Sakuragawa N
Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
[TBL] [Abstract][Full Text] [Related]
4. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
7. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
Barrowcliffe TW; Thomas DP
Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
Meddahi S; Bara L; Fessi H; Samama MM
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of enoxaparin in plasma.
Béguin S; Hemker HC
Acta Chir Scand Suppl; 1990; 556():51-6. PubMed ID: 1963017
[TBL] [Abstract][Full Text] [Related]
12. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Bendayan P; Boccalon H; Dupouy D; Boneu B
Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
14. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
15. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
16. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
Fernandez FA; Buchanan MR; Hirsh J; Fenton JW; Ofosu FA
Thromb Haemost; 1987 Jun; 57(3):286-93. PubMed ID: 3116701
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma.
Hemker HC; Béguin S
Haemostasis; 1990; 20 Suppl 1():81-92. PubMed ID: 1964667
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
Suzuki N; Kitazato K; Takamatsu J; Saito H
Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
